ARCHIVES

Advisors Voted For Provenge Approval Despite Fundamental Flaws In Trials.

This article is from The Cancer Letter archive.

Vol. 33 No. 14 | April 13, 2007

Download PDF Visit The Full Archive

Related Articles

IVAX And It’s Portfolio

December 22, 1994

When Is A Cancer Cured? NCI Suggest One-Year Survival Rates Useful In Determining Advances

August 1, 1975

NCI Rethinks Cancer Center Grants

March 14, 2014

Mihich Subcommittee Recommendations For Augmenting Agents In BRMP Described

December 7, 1979

Saul Rivin Receives ACCC Clinical Research Award.

December 1, 2000

New Chemotherapy, Other Modality Progress Described

March 30, 1979